Resources
68 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/26/2023 (updated 3/26/2024)
Given the smaller size of our cohort, our goal was to create an opportunity for personal interactions, in-person peer-to-peer discussion, and facilitated peer-to-peer learning.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 10/12/2023 (updated 3/27/2024)
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 10/3/2022 (updated 3/27/2024)
The United States overdose crisis continues unabated. Despite efforts to increase capacity for treating opioid use disorder (OUD) in the U.S., how actual treatment receipt compares to need remains unclear. In this cross-sectional study, progress is estimated in addressing the gap between OUD prevalence and OUD treatment receipt at the national and state levels from 2010 to 2019.
Posted 6/3/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of Medication-Assisted Treatment (MAT) retention was highlighted.
Posted 6/6/2022 (updated 3/27/2024)
There are many pathways of recovery from substance use disorder, and all are cause for celebration. This panel featured diverse faces and voices representing a variety of recovery experience including elements of medications for opioid use disorder, alcohol-free recreation, harm reduction mutual aid, outdoor hobbies, yoga and meditation, recovery-supportive housing, collegiate recovery, 12-step mutual aid, and more.
Posted 6/7/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of MAT retention were highlighted. (Repeated from Day 1 Session 4A on Tuesday, April 5th).